Company intelligence / Profile preview

Protaryx Medical

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Protaryx Medical has developed a next‑generation transseptal puncture device that enables zero‑exchange, highly echogenic, atraumatic access to the left atrium for structural heart interventions; a first‑in‑human study in 5 patients in Paraguay met all procedural success endpoints with minimal fluoroscopy, no adverse events, and all patients discharged within 24 hours, and the company is preparing for 510(k) submission.[1][3]

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Protaryx Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protaryx Medical.

Explore the full profile